Xcout IntelNeXtGen Biologics, INC
NeXtGen Biologics, Inc. is a medical equipment manufacturing and biotechnology company located in Alachua, Florida, specializing in advanced regenerative medicine.
Subscribe to see NeXtGen Biologics, INC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
NeXtGen Biologics, INC at a glance
NeXtGen Biologics, INC is a biotechnology company headquartered in United States. It has raised at least $6.7M across the 6 funding rounds on record. Its most recent funding round, Offline Round, raised $130,000 in July 2025. Xcout tracks 12 named people at NeXtGen Biologics, INC, including Jonelle Toothman (Chief Executive Officer).
NeXtGen Biologics, INC leadership
- Jonelle ToothmanChief Executive Officer
- Jonelle ToothmanCEO, CO-FOUNDER
- Jamie GroomsCo-Founder
- JR ManautouSr. Operations Manager
- Dan HamisterDirector
- Elad LevyDirector
6 more named people on record for NeXtGen Biologics, INC, with roles, board committees and tenure — see the full roster →
NeXtGen Biologics, INC funding rounds
At least $6.7M raised across the 6 rounds on record. The 5 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Offline Round | $130,000 | — | |
| — | $1.3M | — | |
| SEC Form D filing | $100,000 | — | |
| SEC Form D filing | $2.2M | — | |
| SEC Form D filing | $1.5M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
NeXtGen Biologics, INC competitors
A few of NeXtGen Biologics, INC's closest competitors — see the full list of competitors and alternatives →
Tiger BioSciences is a medical technology company that specializes in regenerative medicine, developing cellular, acellular, and matrix-like products for wound care and aesthetic treatments. The company also manages human tissue recovery programs to supply biological materials for clinical applications. It serves healthcare providers and medical professionals globally.
Regenity Biosciences is a medical device supplier and biotechnology company headquartered in Paramus, New Jersey, specializing in regenerative medicine and collagen matrix products with nearly 30 years of history.
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
Precise Bio, Inc. is a clinical-stage regenerative medicine company that grows live organs for transplant using 3D bio-printing technology.
Get NeXtGen Biologics, INC's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on NeXtGen Biologics, INC in Xcout Intel
- 12 named people with titles, LinkedIn and board committees
- 6 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access